iBio (IBIO) director awarded 13,500 stock options at $1.00
iBio, Inc. reported a stock-based compensation grant to one of its directors.
Rhea-AI Filing Summary
iBio, Inc. reported a stock-based compensation grant to one of its directors. On 11/20/2025, the director received a stock option to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share. The option becomes exercisable gradually, vesting in equal monthly installments over twelve months starting on the grant date, and expires on 11/19/2035 if not exercised. The filing indicates the director holds these options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 13,500 shares
Grant/Award
1 txn
Insider
Arkowitz David
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 13,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 13,500 contracts (Direct)
Footnotes (1)
- F1. These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.
FAQ
What insider transaction did IBIO report in this Form 4?
The company reported a grant of stock options to a director, covering 13,500 shares of iBio, Inc. common stock at an exercise price of $1.00 per share.
What is the exercise price of the new IBIO director stock options?
The stock options granted to the director have an exercise price of $1.00 per share of iBio, Inc. common stock.
When do the IBIO director stock options vest?
The options vest pro rata on a monthly basis over twelve months commencing on the grant date of 11/20/2025.
When do the IBIO director stock options expire?
The director’s stock options expire on 11/19/2035 if they are not exercised before that date.
Is the IBIO director’s stock option ownership direct or indirect?
The Form 4 states that the 13,500 stock options are held with direct ownership by the reporting person.
AI-generated analysis. How Rhea-AI works. Not financial advice.